Satoshi Ueha

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 5

Top Topics

Hematopoietic Stem Cell

Acute Lymphoblastic Leukemia

Immune Response

Top Venues

Proceedings of the Japan Academy. Series B, Physical and biological sciences

Nature communications

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Yuichi Tsuchiya, Takao Seki, Kenta Kobayashi, Sachiko Komazawa-Sakon, Shigeyuki Shichino, Takashi Nishina, Kyoko Fukuhara, Kenichi Ikejima, Hidenari Nagai, Yoshinori Igarashi, Satoshi Ueha, Akira Oikawa, Shinya Tsurusaki, Soh Yamazaki, Chiharu Nishiyama, Tetuo Mikami, Hideo Yagita, Ko Okumura, Taketomo Kido, Atsushi Miyajima, Kouji Matsushima, Mai Imasaka, Kimi Araki, Toru Imamura, Masaki Ohmuraya, Minoru Tanaka, Hiroyasu Nakano
Fibroblast growth factor 18 stimulates the proliferation of hepatic stellate cells, thereby inducing liver fibrosis. Nature communications 14 (1) (2023)
Kouji Matsushima, Shigeyuki Shichino, Satoshi Ueha
Thirty-five years since the discovery of chemotactic cytokines, interleukin-8 and MCAF: A historical overview. Proceedings of the Japan Academy. Series B, Physical and biological sciences 99 (7) (2023)
Hiroyasu Aoki, Mikiya Tsunoda, Haru Ogiwara, Haruka Shimizu, Haruka Abe, Tatsuro Ogawa, Takaya Abe, Shigeyuki Shichino, Kouji Matsushima, Satoshi Ueha
Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses. Cancer immunology research (2023)
Hiroyasu Aoki, Satoshi Ueha, Yoshiaki Nakamura, Shigeyuki Shichino, Hiromichi Nakajima, Manami Shimomura, Akihiro Sato, Tetsuya Nakatsura, Takayuki Yoshino, Kouji Matsushima
Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. Cancer science 112 (8) (2021)
Satoshi Ueha, Shoji Yokochi, Yoshiro Ishiwata, Mizuha Kosugi-Kanaya, Yusuke Shono, Shiro Shibayama, Satoru Ito, Kouji Matsushima
Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Cancer science 108 (10) (2017)